CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population

European Journal of Clinical Pharmacology

Volumn 58, Issue 8, 2002, Pages 533-535

  Niewinski, P ^a   Orzechowska Juzwenko, K ^a   Hurkacz, M ^a   Rzemislawska, Z ^a   Jazwinska Tarnawska E ^a   Milejski, P ^a   Forkasiewicz, Z ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

CYP2D6; CYP2D6 genotype; CYP2D6 phenotype; Sparteine

Indexed keywords

CYTOCHROME P450 2D6; SPARTEINE;

ADULT; AGED; ALLELE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOGENOMICS; PHENOTYPIC VARIATION; POLAND; POLYMERASE CHAIN REACTION; POPULATION DISTRIBUTION; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; AGED; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLAND; SPARTEINE; VARIATION (GENETICS);

EID: 0036450667     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0505-y     Document Type: Article

References (17)

1. Wolf CR, Smith G (1999) Pharmacogenetics. Br Med Bull 55:366-386
2. Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: Clinical aspects. Pharmacol Ther 46:377-394
3. Alvan G (1991) Clinical consequences of polymorphic drug oxidation. Fundam Clin Pharmacol 5:209-228
4. Orzechowska-Juzwenko K (1992) Clinical consequences of the genetically determined drug oxidation polymorphism. Pol Tygodnik Lekarski 47:1173-1178
5. Kaisary, et al (1987) Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 47:5488-5493
6. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzales FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201
7. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51:12-17
8. Sachse C, Brockmöller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in Caucasian population: Allele frequencies and phenotyping consequences. Am J Hum Genet 60:284-295
9. Smith C, Gough A, Leigh P, Summers B, Harding A (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375-1377
10. Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39:533-537
11. Horai Y, Ishizaki T, Eichelbaum M, Hashimoto K, Chiba K, Dengler HJ (1989) Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations. Xenobiotica 18:1077-1084
12. Agundez JAG, Martinez C, Ledesma MC, Ladona MG, Ladero JM, Benitez J (1994) Genetic basis for differences in debrisoquine polymorphism between a Spanish and other white population. Clin Pharmacol Ther 55:412-417
13. Kunicki PK, Sitkiewicz D, Pawlik A, Bielicka-Sulzyc W, Borowiecka E, Gawronska-Szklarz B, Sterna R, et al (1995) Debrisoquine hydroxylation in a Polish population. Eur J Clin Pharmacol 47:503-505
14. Gawronska-Szklarz B, Wójcicki M, Kuprianowicz A, Kȩdzierska K, Kȩdzierski M, Górnik W, Pawlik A (1999) CYP2D6 and GSTM1 genotypes in a Polish population. Eur J Clin Pharmacol 55:389-392
15. Orzechowska-Juzwenko K, Pawlik J, Niewinski P, Milejski P, Dembowski J, Turek J, Gozdzik A, Swiebodzki L, Hora Z (1994) Genetically determined sparteine oxidation polymorphism in a Polish population. Eur J Clin Pharmacol 46:481-483
16. Griese EU, Zanger UM, Breudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26
17. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM (2000) Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10:577-581